Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.

Khanna S, John JP, Reddy LP.

Psychoneuroendocrinology. 2001 Feb;26(2):209-23.

PMID:
11087965
2.

Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.

de Leeuw AS, Westenberg HG.

J Psychiatr Res. 2008 Sep;42(11):894-901. doi: 10.1016/j.jpsychires.2007.09.001. Epub 2008 Jun 3.

PMID:
18533183
3.

m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.

Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR.

Biol Psychiatry. 1995 Aug 1;38(3):138-49.

PMID:
7578657
4.

Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.

Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR.

Arch Gen Psychiatry. 1988 Feb;45(2):177-85.

PMID:
3337615
5.

Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.

Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR.

Psychiatry Res. 1991 Jan;36(1):1-17.

PMID:
2017519
6.

Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.

Pigott TA, Zohar J, Hill JL, Bernstein SE, Grover GN, Zohar-Kadouch RC, Murphy DL.

Biol Psychiatry. 1991 Mar 1;29(5):418-26.

PMID:
2018816
7.

Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.

Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR.

Arch Gen Psychiatry. 1992 Jan;49(1):21-8.

PMID:
1728249
8.

The serotonin hypothesis of obsessive compulsive disorder.

Barr LC, Goodman WK, Price LH.

Int Clin Psychopharmacol. 1993 Nov;8 Suppl 2:79-82.

PMID:
8201248
9.
10.

Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.

Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J.

Neuropsychobiology. 2004;50(3):200-5.

PMID:
15365215
11.

Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.

Hadigan CM, Walsh BT, Buttinger C, Hollander E.

Biol Psychiatry. 1995 Apr 15;37(8):504-11.

PMID:
7619973
12.

Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.

Bastani B, Nash JF, Meltzer HY.

Arch Gen Psychiatry. 1990 Sep;47(9):833-9.

PMID:
2203327
13.
14.

The MCPP challenge test in schizophrenia: hormonal and behavioral responses.

Iqbal N, Asnis GM, Wetzler S, Kahn RS, Kay SR, van Praag HM.

Biol Psychiatry. 1991 Oct 15;30(8):770-8.

PMID:
1751620
15.

Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.

Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL.

Arch Gen Psychiatry. 1987 Nov;44(11):946-51.

PMID:
3675134
16.
17.

A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.

Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL.

Biol Psychiatry. 1993 Jan 1;33(1):3-14.

PMID:
8420593
18.
19.

Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.

Broocks A, Pigott TA, Hill JL, Canter S, Grady TA, L'Heureux F, Murphy DL.

Psychiatry Res. 1998 Jun 2;79(1):11-20.

PMID:
9676822
20.

Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.

Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL.

Arch Gen Psychiatry. 1988 Feb;45(2):167-72.

PMID:
3276283

Supplemental Content

Support Center